Clinical trial
A Phase I/II Trial of ZD1839 (Iressa) Given Concurrently With Cisplatin and Radiotherapy in Patients With Locally Advanced Head and Neck Cancer
NCT00239304 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Trial of ZD1839 (Iressa) Given Concurrently With Cisplatin and Radiotherapy in Patients With Locally Advanced Head and Neck Cancer
- Lead sponsor
- AstraZeneca
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- June 30, 2003
- Completion date
- March 31, 2006
- Enrollment
- 40
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.